Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Other Accumulated Expenses: 2021-2025

Historic Other Accumulated Expenses for Abeona Therapeutics (ABEO) over the last 3 years, with Sep 2025 value amounting to $35,000.

  • Abeona Therapeutics' Other Accumulated Expenses rose 3400.00% to $35,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $35,000, marking a year-over-year increase of 3400.00%. This contributed to the annual value of $64,000 for FY2024, which is 6300.00% up from last year.
  • Abeona Therapeutics' Other Accumulated Expenses amounted to $35,000 in Q3 2025, which was down 56.25% from $80,000 recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Other Accumulated Expenses peaked at $317,000 during Q1 2025, and registered a low of $1,000 during Q4 2023.
  • For the 3-year period, Abeona Therapeutics' Other Accumulated Expenses averaged around $100,818, with its median value being $64,000 (2024).
  • In the last 5 years, Abeona Therapeutics' Other Accumulated Expenses tumbled by 99.51% in 2024 and then soared by 31,600.00% in 2025.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Other Accumulated Expenses stood at $296,000 in 2021, then crashed by 31.08% to $204,000 in 2022, then tumbled by 99.51% to $1,000 in 2023, then skyrocketed by 6,300.00% to $64,000 in 2024, then skyrocketed by 3,400.00% to $35,000 in 2025.
  • Its last three reported values are $35,000 in Q3 2025, $80,000 for Q2 2025, and $317,000 during Q1 2025.